Evidence map›Paper›PMID 39840500›Full record

ArticleAdvanced healthcare materials2025

FXa-Responsive Hydrogels to Craft Corneal Endothelial Lamellae.

Mikhail V Tsurkan, Juliane Bessert, Rabea Selzer, Sarah D Tsurkan, Dagmar Pette, Manfred F Maitz, Petra B Welzel, Carsten Werner

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mikhail V TsurkanMax Bergmann Center of Biomaterials Dresden, Leibniz-Institut für Polymerforschung Dresden e. V., Hohe Str. 6, 01069, Dresden, Germany.ORCID 0000-0003-4000-3890
Juliane BessertMax Bergmann Center of Biomaterials Dresden, Leibniz-Institut für Polymerforschung Dresden e. V., Hohe Str. 6, 01069, Dresden, Germany.
Rabea SelzerMax Bergmann Center of Biomaterials Dresden, Leibniz-Institut für Polymerforschung Dresden e. V., Hohe Str. 6, 01069, Dresden, Germany.
Sarah D TsurkanTissueGUARD GmbH, Trienter Str 16, 01217, Dresden, Germany.
Dagmar PetteMax Bergmann Center of Biomaterials Dresden, Leibniz-Institut für Polymerforschung Dresden e. V., Hohe Str. 6, 01069, Dresden, Germany.
Manfred F MaitzMax Bergmann Center of Biomaterials Dresden, Leibniz-Institut für Polymerforschung Dresden e. V., Hohe Str. 6, 01069, Dresden, Germany.
Petra B WelzelMax Bergmann Center of Biomaterials Dresden, Leibniz-Institut für Polymerforschung Dresden e. V., Hohe Str. 6, 01069, Dresden, Germany.
Carsten WernerMax Bergmann Center of Biomaterials Dresden, Leibniz-Institut für Polymerforschung Dresden e. V., Hohe Str. 6, 01069, Dresden, Germany.

Funding

Bundesministerium für Wirtschaft und Klimaschutz 03EFJSN114Deutsche Forschungsgemeinschaft EN168/13-1Deutsche Forschungsgemeinschaft NI709/4-1
6 · The paper itself

Abstract

Cell-instructive polymer hydrogels are instrumental in tissue engineering for regenerative therapies. Implementing defined and selective responsiveness to external stimuli is a persisting challenge that critically restricts their functionality. Addressing this challenge, this study introduces a versatile, modular hydrogel system composed of four-arm poly(ethylene glycol)(starPEG)-peptide and glycosaminoglycan(GAG)-maleimide conjugates. The gel system features a small peptide sequence that is selectively cleaved by the coagulation factor FXa. In a cell culture environment, where active FXa is absent, the hydrogel remains stable, providing a conducive matrix for the growth of complex tissue structures or organoids. Upon the introduction of FXa, the hydrogel is designed to disintegrate rapidly, enabling the gentle release of the cultivated tissues without impairing their functionality. The efficacy of this approach is demonstrated through the ex vivo development, detachment, and transplantation of human corneal endothelial lamellae, achieving sizes relevant for clinical application in Descemet Membrane Endothelial Keratoplasty (DMEK). Furthermore, the practicality of the hydrogel system is validated in vitro using a de-endothelialized porcine cornea as a surrogate recipient. Since the FXa-cleavable peptide can be integrated into a variety of multifunctional hydrogels, it can pave the way for next-generation scaffold-free tissue engineering and organoid regenerative therapies.

Indexed as

Endothelium, CornealHydrogelsAnimalsGlycosaminoglycansHumansPeptidesPolyethylene GlycolsSwineTissue EngineeringGlycosaminoglycansHydrogelsPeptidesPolyethylene Glycolsbiorthogonalcorneal endothelial lamellaehydrogelstimuli‐responsive hydrogeltissue engineering

Identifiers

PMID39840500
PMCPMC12004427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.